Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

metabolic anti-cancer agent ASCA101

An agent targeting cancer metabolic processes, with potential antineoplastic activity. Upon administration, metabolic anti-cancer agent ASCA101 may disrupt one or more specific metabolic processes in cancer cells, which may lead to an increase in reactive oxygen species (ROS) and adenosine-5'-triphosphate (ATP) depletion. This causes apoptosis and prevents proliferation of susceptible cancers cells only while sparing normal, healthy cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	ASCA 101 ASCA-101 ASCA101

metabolic anti-cancer agent ASCA101

Search NCI's Drug Dictionary